Test_RG2
Name of the Team/Group: Test_RG2
Institution: Hospital Lisbon
City: Lisbon
Country: Portugal
Principal Investigator name: Someone
Number of researchers: 3
Number of PhD students: 2
Number of Postdoc: 3
Type of research
- Epidemiology
Resources available
- Databases
Contacts
C/Random in Portugal
Telephone:
54543434123
Email:
lisbon@gmail.com
Website
lisbon.group.pt
Group Description
Brief description of the Group
publication1
Test RG 01
Name of the Team/Group: Test RG 01
Institution: Test RG 01
City: Test RG 01
Country: Italy
Principal Investigator name: PI NAME
Number of researchers: 21
Number of PhD students: 28
Number of Postdoc: 21
Type of research
- Oncology
Resources available
- Databases
Group Description
Test RG 01
Top publication 1
Top publication title 2
Top publication title 3
Top publication title 4
Top publication title 5
Genetic and Molecular Epidemiology Group
Name of the Team/Group: Genetic and Molecular Epidemiology Group
Institution: Spanish National Cancer Research Center (CNIO)
City: Madrid
Country: Spain
Principal Investigator name: Núria Malats
Number of researchers: 0
Number of PhD students: 4
Number of Postdoc: 0
Type of research
- Basic
Resources available
- Bioinformatics databases
Group Description
The scope of the research carried out by the Genetic and Molecular Epidemiology Group (GMEG) ranges from the identification of aetiological agents and genetic pathways to the translation of the findings into the clinical and public health domains, focusing on bladder, pancreatic, and breast cancers.
We employ a wide variety of biomarkers, including omics data, to better characterise exposures, genetic susceptibility patterns, and cancer outcomes. While omics data provide a unique opportunity in this regard, their integration with non-omics data poses important challenges, and GMEG explores this methodological field in epidemiologic studies.
The strategic goals of the Group are to:
- Identify non-genetic and genetic factors, as well as their interactions, associated with cancer development and progression and with its molecular/omics subphenotypes.
- Develop and apply statistical/informatics tools to model the risk and course of patients with cancer by integrating epidemiological and clinical data with omics information.
- Assess clinical and public health strategies for cancer control using newly developed biomarkers and algorithms.
Kartal E, Schmidt TSB, Molina-Montes E, Rodríguez-Perales S, Wirbel J, Maistrenko OM, Akanni WA, Alashkar Alhamwe B, Alves RJ, Carrato A, Erasmus HP, Estudillo L, Finkelmeier F, Fullam A, Glazek AM, Gómez-Rubio P, Hercog R, Jung F, Kandels S, Kersting S, Langheinrich M, Márquez M, Molero X, Orakov A, Van Rossum T, Torres-Ruiz R, Telzerow A, Zych K; MAGIC Study investigators; PanGenEU Study investigators, Benes V, Zeller G, Trebicka J, Real FX, Malats N, Bork P. (2022). A faecal microbiota signature with high specificity for pancreatic cancer. Gut 71, 1359-1372.
Molina-Montes E, Coscia C, Gómez-Rubio P, Fernández A, Rianne Boenink R, Rava M, Márquez M, Molero X, Löhr M, Sharp L, Michalski CW, Farré A, Perea J, O'Rorke M, Greenhalf W, Iglesias M, Tardón A, Gress T, Barberà VM, Crnogorac-Jurcevic T, Muñoz-Bellvís L, Domínguez-Muñoz E, Harald Renz H, Balsells J, Costello E, Ilzarbe L, Jörg Kleeff J, Kong B, Mora J, O'Driscoll D, Poves I, Scarpa A, Yu J, Hidalgo M, Lawlor RT, Ye W, Carrato A, Real FX, Malats N, on behalf of the PanGenEU Study Investigators (2021). Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes, and obesity/BMI through causal inference and mediation analyses.. Gut 70, 319-329.
López de Maturana E, Rodríguez JA, Alonso L, Lao O, Molina-Montes E, Martín-Antoniano IA, Gómez-Rubio P, Lawlor R, Carrato A, Hidalgo M, Iglesias M, Molero X, Löhr M, Michalski C, Perea J, O'Rorke M, Barberà VM, Tardón A, Farré A, Muñoz-Bellvís L, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Gress T, Greenhalf W, Sharp L, Arnes L, Cecchini L, Balsells J, Costello E, Ilzarbe L, Kleeff J, Kong B, Márquez M, Mora J, O'Driscoll D, Scarpa A, Ye W, Yu J; PanGenEU Investigators, García-Closas M, Kogevinas M, Rothman N, Silverman DT; SBC/EPICURO Investigators, Albanes D, Arslan AA, Beane-Freeman L, Bracci PM, Brennan P, Bueno-de-Mesquita B, Buring J, Canzian F, Du M, Gallinger S, Gaziano JM, Goodman PJ, Gunter M, LeMarchand L, Li D, Neale RE, Peters U, Petersen GM, Risch HA, Sánchez MJ, Shu XO, Thornquist MD, Visvanathan K, Zheng W, Chanock SJ, Easton D, Wolpin BM, Stolzenberg-Solomon RZ, Klein AP, Amundadottir LT, Marti-Renom MA, Real FX, Malats N (2021). A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome Med 13, 15.